المؤلفون: Mansour, Alexandre, Flecher, Erwan, Schmidt, Matthieu, Rozec, Bertrand, Gouin-Thibault, Isabelle, Esvan, Maxime, Fougerou, Claire, Levy, Bruno, Porto, Alizée, Ross, James, Para, Marylou, Manganiello, Sabrina, Lebreton, Guillaume, Vincentelli, André, Nesseler, Nicolas, Pierrot, Marc, Chocron, Sidney, Flicoteaux, Guillaume, Mauriat, Philippe, Ouattara, Alexandre, Roze, Hadrien, Huet, Olivier, Fischer, Marc-Olivier, Alessandri, Claire, Bellaïche, Raphel, Constant, Ophélie, de Roux, Quentin, Ly, André, Meffert, Arnaud, Merle, Jean-Claude, Mongardon, Nicolas, Picard, Lucile, Skripkina, Elena, Folliguet, Thierry, Fiore, Antonio, D’ostrevy, Nicolas, Morgan, Marie-Catherine, Guinot, Pierre-Grégoire, Nguyen, Maxime, Gaide-Chevronnay, Lucie, Terzi, Nicolas, Colin, Gwenhaël, Fabre, Olivier, Astaneh, Arash, Issard, Justin, Fadel, Elie, Fabre, Dominique, Girault, Antoine, Guihaire, Julien, Ion, Iolande, Menager, Jean Baptiste, Mitilian, Delphine, Mercier, Olaf, Stephan, François, Thes, Jacques, Jouan, Jerôme, Duburcq, Thibault, Loobuyck, Valentin, Moussa, Mouhammed, Mugnier, Agnes, Rousse, Natacha, Desebbe, Olivier, Fellahi, Jean-Luc, Henaine, Roland, Pozzi, Matteo, Richard, Jean-Christophe, Riad, Zakaria, Guervilly, Christophe, Hraiech, Sami, Papazian, Laurent, Castanier, Matthias, Chanavaz, Charles, Cadoz, Cyril, Gette, Sebastien, Louis, Guillaume, Portocarrero, Erick, Gaudard, Philippe, Brini, Kais, Bischoff, Nicolas, Kimmoun, Antoine, Mattei, Mathieu, Perez, Pierre, Bourdiol, Alexandre, Hourmant, Yannick, Mahé, Pierre-Joachim, Jaquet, Pierre, Lortat-Jacob, Brice, Mordant, Pierre, Nataf, Patrick, Patrier, Juliette, Provenchère, Sophie, Roué, Morgan, Sonneville, Romain, Tran-Dinh, Alexy, Wicky, Paul-Henri, Al Zreibi, Charles, Cholley, Bernard, Guyonvarch, Yannis, Hamada, Sophie, Harrois, Anatole, Matiello, Jordi, Kerforne, Thomas, Lacroix, Corentin, Brechot, Nicolas, Combes, Alain, Chommeloux, Juliette, Constantin, Jean Michel, D’alessandro, Cosimo, Demondion, Pierre, Demoule, Alexandre, Dres, Martin, Fadel, Guillaume, Fartoukh, Muriel, Hekimian, Guillaume, Juvin, Charles, Leprince, Pascal, Levy, David, Luyt, Charles Edouard, Pineton de Chambrun, Marc, Schoell, Thibaut, Fillâtre, Pierre, Massart, Nicolas, Nicolas, Roxane, Jonas, Maud, Vidal, Charles, Allou, Nicolas, Muccio, Salvatore, Di Perna, Dario, Ruggieri, Vito-Giovanni, Mourvillier, Bruno, Anselmi, Amedeo, Bounader, Karl, Launey, Yoann, Lebouvier, Thomas, Parasido, Alessandro, Reizine, Florian, Seguin, Philippe, Besnier, Emmanuel, Carpentier, Dorothée, Clavier, Thomas, Falcoz, Pierre-Emmanuel, Olland, Anne, Villard, Marion, Bounes, Fanny, Labaste, François, Minville, Vincent, Guillon, Antoine, Fedun, Yannick

المساهمون: Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 RNMCD

الوصف: 48 ; 8

وصف الملف: application/octet-stream

العلاقة: Intensive Care Medicine; http://hdl.handle.net/20.500.12210/108496Test

الإتاحة: https://doi.org/20.500.12210/108496Test
https://hdl.handle.net/20.500.12210/108496Test

المؤلفون: Overtchouk, Pavel, Folliguet, Thierry, Pinaud, Frederic, Fouquet, Oliver, Pernot, Mathieu, Bonnet, Guillaume, Hubert, Maxime, Lapeze, Joel, Claudel, Jean-Philippe, Ghostine, Said, Azmoun, Alexandre, Caussin, Christophe, Zannis, Konstantinos, Harmouche, Majid, Verhoye, Jean-Philippe, Lafont, Antoine, Chamandi, Chekrallah, Ruggieri, Vito Giovanni, Di Cesare, Alessandro, Leclercq, Florence, Gandet, Thomas, Modine, Thomas

المساهمون: CHU Lille, CNRS, Inserm, Université de Lille, Troubles cognitifs dégénératifs et vasculaires - U1171, Troubles cognitifs dégénératifs et vasculaires - U 1171 TCDV

مصطلحات موضوعية: Sapien 3, transcarotid, TAVR

الوصف: OBJECTIVE: This study sought to describe the procedural and clinical outcomes of patients undergoing transcarotid (TC) transcatheter aortic valve replacement (TAVR) with the Edwards Sapien 3 device. BACKGROUND: The TC approach for TAVR holds the potential to become the optimal alternative to the transfemoral gold standard. Limited data exist regarding safety and efficacy of TC-TAVR using the Edwards Sapien 3 device. METHODS: The French Transcarotid TAVR prospective multicenter registry included patients between 2014 and 2018. Consecutive patients treated in 1 of the 13 participating centers ineligible for transfemoral TAVR were screened for TC-TAVR. Clinical and echocardiographic data were prospectively collected. Perioperative and 30-day outcomes were reported according to the updated Valve Academic Research Consortium (VARC-2). RESULTS: A total of 314 patients were included with a median (interquartile range) age of 83 (78 to 88) years, 63% were males, Society of Thoracic Surgeons mortality risk score 5.8% (4% to 8.3%). Most patients presented with peripheral artery disease (64%). TC-TAVR was performed under general anesthesia in 91% of cases, mostly using the left carotid artery (73.6%) with a procedural success of 97%. Three annulus ruptures were reported, all resulting in patient death. At 30 days, rates of major bleeding, new permanent pacemaker, and stroke or transient ischemic attack were 4.1%, 16%, and 1.6%, respectively. The 30-day mortality was 3.2%. CONCLUSIONS: TC-TAVR using the Edwards Sapien 3 device was safe and effective in this prospective multicenter registry. The TC approach might be considered, in selected patients, as the first-line alternative approach for TAVR whenever the transfemoral access is prohibited. Sapien 3 device was safe and effective in our multicenter cohort.

العلاقة: JACC. Cardiovascular interventions; JACC Cardiovasc Interv; http://hdl.handle.net/20.500.12210/16513Test

الإتاحة: https://doi.org/20.500.12210/16513Test
https://hdl.handle.net/20.500.12210/16513Test

المؤلفون: Folliguet, Thierry A., Teiger, Emmanuel, Beurtheret, Sylvain, Modine, Thomas, Lefevre, Thierry, Van Belle, Eric, Gilard, Martine, Eltchaninoff, Helene, Koning, Rene, Iung, Bernard, Verhoye, Jean-Philippe, Leprince, Pascal, Le Breton, Herve, Lafont, Antoine, Parolari, Alessandro, Barili, Fabio

المساهمون: CHU Lille, Inserm, Institut Pasteur de Lille, Université de Lille, Troubles cognitifs dégénératifs et vasculaires - U 1171 TCDV, Troubles cognitifs dégénératifs et vasculaires - U1171, Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011, Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 RNMCD

مصطلحات موضوعية: Access site, Aortic valve, Carotid, Outcome, Vascular complications

العلاقة: European journal of cardio-thoracic surgery . official journal of the European Association for Cardio-thoracic Surgery; Eur J Cardiothorac Surg; http://hdl.handle.net/20.500.12210/40140Test

الإتاحة: https://doi.org/20.500.12210/40140Test
https://hdl.handle.net/20.500.12210/40140Test

المؤلفون: Folliguet, Thierry A, Teiger, Emmanuel, Beurtheret, Sylvain, Modine, Thomas, Lefevre, Thierry, van Belle, Eric, Gilard, Martine, Eltchaninoff, Helene, Koning, René, Iung, Bernard, Verhoye, Jean Philippe, Leprince, Pascal, Le Breton, Hervé, Lafont, Antoine, Parolari, Alessandro, Barili, Fabio

المساهمون: CHU Henri Mondor Créteil, Centre Hospitalier Régional Universitaire Lille CHRU Lille, Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 RNMCD, Pharmacologie des Dysfonctionnements Endotheliaux et Myocardiques, Laboratoire Traitement du Signal et de l'Image LTSI, Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, CHU Pitié-Salpêtrière AP-HP, Paris-Centre de Recherche Cardiovasculaire PARCC - UMR-S U970, Istituti di Ricovero e Cura a Carattere Scientifico IRCCS

مصطلحات موضوعية: Access site, Vascular complications, Carotid, Outcome, Aortic valve

الوصف: Objectives - The transcarotid (TC) approach for transcatheter aortic valve implantation (TAVI) is potentially an optimal alternative to the transfemoral (TF) approach. Our goal was to compare the safety and efficacy of TC- and TF-TAVI. Methods - Patients who underwent TF-TAVI or TC-TAVI in the prospectively collected FRANCE TAVI registry between January 2013 and December 2015 were compared. Propensity score inverse probability weighting methods were employed to minimize the impact of bias related to non-random treatment assignment. Results - Of the 11 033 patients included in the current study, 10 598 (96%) underwent a TF-TAVI and 435 (4.1%) had a TC-TAVI. Patients in the TC-TAVI access group presented with a higher risk profile but were significantly younger. There were no differences in the perioperative and 2-year mortality rates after adjustment [odds ratio (OR) 1.02, 95% confidence interval (CI) 0.62-1.68; P = 0.99 and hazard ratio 1.03, 95% CI 0.7-1.35; P = 0.83). TC-TAVI was associated with a significant risk of stroke (OR 2.42, 95% CI 2.01-2.92; P < 0.001), ST-elevation myocardial infarction (OR 7.32, 95% CI 3.87-13.87; P < 0.001), infections (OR 2.36, 95% CI 2.04-2.71; P < 0.001), bleeding (OR 2.01, 95% CI 1.76-2.29; P < 0.001), renal failure (OR 2.23, 95% CI 1.90-2.60; P < 0.001) and need for dialysis (OR 2.36, 95% CI 2.01-2.76, P < 0.001). Conversely, TC-TAVI was not confirmed as a risk factor for pacemaker implantation after adjustment (OR 1.05, 95% CI 0.96-1.15; P < 0.28) and was a protective factor for vascular complications (OR 0.37, 95% CI 0.32-0.43; P < 0.001). Conclusions - TC-TAVI is a safe procedure compared to TF-TAVI, although it holds an increased risk of perioperative complications. It should be considered in case of non-femoral peripheral access as the second access choice, to increase the overall safety of TAVI procedures. ; 56 ; 6

وصف الملف: application/octet-stream

العلاقة: European Journal of Cardio-Thoracic Surgery; http://hdl.handle.net/20.500.12210/96086Test

الإتاحة: https://doi.org/20.500.12210/96086Test
https://hdl.handle.net/20.500.12210/96086Test

المؤلفون: Folliguet, Thierry, Laurent, Nicolas, Bertram, Maxime, Zannis, Konstantinos, Elfarra, Mazen, Vanhuyse, Fabrice, Maureira, Pablo, Modine, Thomas

المساهمون: CHU Lille, CNRS, Inserm, Université de Lille, Troubles cognitifs dégénératifs et vasculaires - U1171, Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 TCDV

مصطلحات موضوعية: Aortic valve implantation, Aortic valve, Carotid artery

الوصف: OBJECTIVE: Transcatheter aortic valve implantation is a well-recognized treatment option for high-risk patients with aortic stenosis. The femoral approach is possible in 80% of cases and remains the access of choice. When this approach is not feasible, other alternative routes have been proposed such as transapical, transaortic and subclavian. Transcarotid aortic valve implantation has been proposed as another direct vascular access. Its use is relatively new and still under evaluation. METHODS: We successfully performed transcarotid aortic valve implantation in 145 consecutive patients through the left or right carotid artery in 3 different French sites over a 2-year period. Data were prospectively entered in the French transcatheter aortic valve implantation database. RESULTS: The mean age was 79.8 ± 8.7 years, with a mean logistic EuroSCORE of 20.7 ± 12.6%. The procedure was successful in all patients, and no conversion was necessary. Thirty-day survival was 93.7%, 8 (5.5%) patients presented either minor or major strokes and 1 patient had a localized asymptomatic carotid dissection. All patients were immediately extubated, and none presented respiratory complications. CONCLUSIONS: Transcarotid aortic valve implantation is a safe alternative to transfemoral transcatheter aortic valve implantation, with direct access to the aortic valve, which can be performed with limited incision. ; 53

العلاقة: European journal of cardio-thoracic surgery . official journal of the European Association for Cardio-thoracic Surgery; Eur. J. Cardio-Thorac. Surg.; http://hdl.handle.net/20.500.12210/16148Test

الإتاحة: https://doi.org/20.500.12210/16148Test
https://hdl.handle.net/20.500.12210/16148Test

المؤلفون: Auffret, Vincent, Lefevre, Thierry, Van Belle, Eric, Eltchaninoff, Helene, Iung, Bernard, Koning, Rene, Motreff, Pascal, Leprince, Pascal, Verhoye, Jean-Philippe, Manigold, Thibaut, Souteyrand, Geraud, Boulmier, Dominique, Joly, Patrick, Pinaud, Frederic, Himbert, Dominique, Collet, Jean Philippe, Rioufol, Gilles, Ghostine, Said, Bar, Olivier, Dibie, Alain, Champagnac, Didier, Leroux, Lionel, Collet, Frederic, Teiger, Emmanuel, Darremont, Olivier, Folliguet, Thierry, Leclercq, Florence, Lhermusier, Thibault, Ohlmann, Patrick, Huret, Bruno, Lorgis, Luc, Drogoul, Laurent, Bertrand, Bernard, Spaulding, Christian, Quilliet, Laurent, Cuisset, Thomas, Delomez, Maxence, Beygui, Farzin, Claudel, Jean-Philippe, Hepp, Alain, Jegou, Arnaud, Gommeaux, Antoine, Mirode, Anfani, Christiaens, Luc, Christophe, Charles, Cassat, Claude, Metz, Damien, Mangin, Lionel, Isaaz, Karl, Jacquemin, Laurent, Guyon, Philippe, Pouillot, Christophe, Makowski, Serge, Bataille, Vincent, Rodes-Cabau, Josep, Gilard, Martine, Le Breton, Herve

المساهمون: CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, Université de Lille, Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011, Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 RNMCD

مصطلحات موضوعية: transfemoral, outcomes, national registry, pacemaker

الوصف: BACKGROUND: Transcatheter aortic valve replacement (TAVR) is standard therapy for patients with severe aortic stenosis who are at high surgical risk. However, national data regarding procedural characteristics and clinical outcomes over time are limited. OBJECTIVE: The aim of this study was to assess nationwide performance trends and clinical outcomes of TAVR during a 6-year period. METHODS: TAVRs performed in 48 centers across France between January 2013 and December 2015 were prospectively included in the FRANCE TAVI (French Transcatheter Aortic Valve Implantation) registry. Findings were further compared with those reported from the FRANCE 2 (French Aortic National CoreValve and Edwards 2) registry, which captured all TAVRs performed from January 2010 to January 2012 across 34 centers. RESULTS: A total of 12,804 patients from FRANCE TAVI and 4,165 patients from FRANCE 2 were included in this analysis. The median age of patients was 84.6 years, and 49.7% were men. FRANCE TAVI participants were older but at lower surgical risk (median logistic European System for Cardiac Operative Risk Evaluation [EuroSCORE]: 15.0% vs. 18.4%; p < 0.001). More than 80% of patients in FRANCE TAVI underwent transfemoral TAVR. Transesophageal echocardiography guidance decreased from 60.7% to 32.3% of cases, whereas more recent procedures were increasingly performed in hybrid operating rooms (15.8% vs. 35.7%). Rates of Valve Academic Research Consortium-defined device success increased from 95.3% in FRANCE 2 to 96.8% in FRANCE TAVI (p < 0.001). In-hospital and 30-day mortality rates were 4.4% and 5.4%, respectively, in FRANCE TAVI compared with 8.2% and 10.1%, respectively, in FRANCE 2 (p < 0.001 for both). Stroke and potentially life-threatening complications, such as annulus rupture or aortic dissection, remained stable over time, whereas rates of cardiac tamponade and pacemaker implantation significantly increased. CONCLUSIONS: The FRANCE TAVI registry provided reassuring data regarding trends in TAVR performance in an ...

العلاقة: Journal of the American College of Cardiology; J. Am. Coll. Cardiol.; http://hdl.handle.net/20.500.12210/16637Test

الإتاحة: https://doi.org/20.500.12210/16637Test
https://hdl.handle.net/20.500.12210/16637Test

المؤلفون: Van Belle, Eric, Vincent, Flavien, Labreuche, Julien, Auffret, Vincent, Debry, Nicolas, Lefèvre, Thierry, Eltchaninoff, Helene, Manigold, Thibaut, Gilard, Martine, Verhoye, Jean-Phillipe, Himbert, Dominique, Koning, Rene, Collet, Jean-Phillipe, Leprince, Pascal, Teiger, Emmanuel, Duhamel, Alain, Cosenza, Alessandro, Schurtz, Guillaume, Porouchani, Sina, Lattuca, Benoit, Robin, Emmanuel, Coisne, Augustin, Modine, Thomas, Richardson, Marjorie, Joly, Patrick, Rioufol, Gilles, Ghostine, Said, Bar, Olivier, Amabile, Nicolas, Champagnac, Didier, Ohlmann, Patrick, Meneveau, Nicolas, Lhermusier, Thibaut, Leroux, Lionel, Leclercq, Florence, Gandet, Thomas, Pinaud, Frédéric, Cuisset, Thomas, Motreff, Pascal, Souteyrand, Géraud, Iung, Bernard, Folliguet, Thierry, Commeau, Philippe, Cayla, Guillaume, Bayet, Gilles, Darremont, Olivier, Spaulding, Christian, Le Breton, Hervé, Delhaye, Cédric

المساهمون: Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 RNMCD, IMRB - SMCD/"Senescence, Metabolism and Cardiovascular Diseases" Créteil U955 Inserm - UPEC

الوصف: Background: No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducted to date. Methods: From January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valve Bioprostheses Established by Catheter) included 12 141 patients undergoing BE-THV (Edwards, n=8038) or SE-THV (Medtronic, n=4103) for treatment of native aortic stenosis. Long term mortality status was available in all patients (median 20 months; interquartile range, 14 to 30). Patients treated with BE-THV (n=3910) were successfully matched 1:1 with 3910 patients treated with SE-THV by using propensity score (25 clinical, anatomical, and procedural variables) and by date of the procedure (within 3 months). The first coprimary outcome was ≥ moderate occurrence of paravalvular regurgitation or in-hospital mortality, or both. The second coprimary outcome was 2-year all-cause mortality. Results: In propensity–matched analyses, the incidence of the first coprimary outcome was higher with SE-THV (19.8%) compared with BE-THV (11.9%; relative risk, 1.68 [95% CI, 1.46–1.91]; P <0.0001). Each component of the outcome was also higher in patients receiving SE-THV: ≥ moderate paravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [95% CI, 1.63–2.22]; P <0.0001) and in hospital mortality (5.6% versus 4.2%; relative risk, 1.34 [95% CI, 1.07–1.66]; P =0.01). During follow up, all cause mortality occurred in 899 patients treated with SE-THV (2-year mortality, 29.8%) and in 801 patients treated with BE-THV (2-year mortality, 26.6%; hazard ratio, 1.17 [95% CI, 1.06–1.29]; P =0.003). Similar results were found using inverse probability of treatment weighting using propensity score analysis. Conclusion: The present study suggests that use of SE-THV was associated with a higher risk of paravalvular regurgitation and higher in-hospital and 2-year mortality compared with use of BE-THV. ...

العلاقة: Circulation; http://hdl.handle.net/20.500.12210/106080Test

الإتاحة: https://doi.org/20.500.12210/106080Test
https://hdl.handle.net/20.500.12210/106080Test